164 related articles for article (PubMed ID: 38700261)
1. Systematic identification of pharmacogenomics information from clinical trials.
Li J; Lu Z
J Biomed Inform; 2012 Oct; 45(5):870-8. PubMed ID: 22546622
[TBL] [Abstract][Full Text] [Related]
2. A systematic review and meta-analysis of the impacts of germline pharmacogenomics on severe toxicity and symptom burden in adult patients with cancer.
Lingaratnam S; Shah M; Nicolazzo J; Michael M; Seymour JF; James P; Lazarakis S; Loi S; Kirkpatrick CMJ
Clin Transl Sci; 2024 May; 17(5):e13781. PubMed ID: 38700261
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.
Weibel S; Rücker G; Eberhart LH; Pace NL; Hartl HM; Jordan OL; Mayer D; Riemer M; Schaefer MS; Raj D; Backhaus I; Helf A; Schlesinger T; Kienbaum P; Kranke P
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012859. PubMed ID: 33075160
[TBL] [Abstract][Full Text] [Related]
5. Potentially actionable pharmacogenetic variants and symptom control medications in oncology.
Patel JN; Boselli D; Jandrisevits EJ; Hamadeh IS; Salem A; Meadors P; Walsh D
Support Care Cancer; 2021 Oct; 29(10):5927-5934. PubMed ID: 33758969
[TBL] [Abstract][Full Text] [Related]
6. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481
[TBL] [Abstract][Full Text] [Related]
7. Unraveling heterogeneity of the clinical pharmacogenomic guidelines in oncology practice among major regulatory bodies.
Nagy M; Attya M; Patrinos GP
Pharmacogenomics; 2020 Nov; 21(17):1247-1264. PubMed ID: 33124490
[TBL] [Abstract][Full Text] [Related]
8. Survival of Patients With Cancer With
Knikman JE; Wilting TA; Lopez-Yurda M; Henricks LM; Lunenburg CATC; de Man FM; Meulendijks D; Nieboer P; Droogendijk HJ; Creemers GJ; Mandigers CMPW; Imholz ALT; Mathijssen RHJ; Portielje JEA; Valkenburg-van Iersel L; Vulink A; van der Poel MHW; Baars A; Swen JJ; Gelderblom H; Schellens JHM; Beijnen JH; Guchelaar HJ; Cats A
J Clin Oncol; 2023 Dec; 41(35):5411-5421. PubMed ID: 37639651
[TBL] [Abstract][Full Text] [Related]
9. The pharmacogenomic landscape of an Indigenous Australian population.
Samarasinghe SR; Hoy W; Jadhao S; McMorran BJ; Guchelaar HJ; Nagaraj SH
Front Pharmacol; 2023; 14():1180640. PubMed ID: 37284308
[No Abstract] [Full Text] [Related]
10. Editorial: Pharmacogenetics and pharmacogenomics in Latin America: ethnic variability, new insights in advances and perspectives: a RELIVAF-CYTED initiative, Volume II.
López-Cortés A; Esperón P; Martínez MF; Redal MA; Lazarowski A; Varela NM; Lares-Asseff I; Quiñones LA
Front Pharmacol; 2023; 14():1211712. PubMed ID: 37205907
[No Abstract] [Full Text] [Related]
11. A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study.
Swen JJ; van der Wouden CH; Manson LE; Abdullah-Koolmees H; Blagec K; Blagus T; Böhringer S; Cambon-Thomsen A; Cecchin E; Cheung KC; Deneer VH; Dupui M; Ingelman-Sundberg M; Jonsson S; Joefield-Roka C; Just KS; Karlsson MO; Konta L; Koopmann R; Kriek M; Lehr T; Mitropoulou C; Rial-Sebbag E; Rollinson V; Roncato R; Samwald M; Schaeffeler E; Skokou M; Schwab M; Steinberger D; Stingl JC; Tremmel R; Turner RM; van Rhenen MH; Dávila Fajardo CL; Dolžan V; Patrinos GP; Pirmohamed M; Sunder-Plassmann G; Toffoli G; Guchelaar HJ;
Lancet; 2023 Feb; 401(10374):347-356. PubMed ID: 36739136
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics as a predictor chemotherapy induced peripheral neuropathy in gynecologic cancer patients treated with Taxane-based chemotherapy.
Mysona D; Dorr K; Ward A; Shaver E; Rungruang B; Ghamande S
Gynecol Oncol; 2023 Jan; 168():114-118. PubMed ID: 36434945
[TBL] [Abstract][Full Text] [Related]
13. Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
Rugo HS; Tolaney SM; Loirat D; Punie K; Bardia A; Hurvitz SA; O'Shaughnessy J; Cortés J; Diéras V; Carey LA; Gianni L; Piccart MJ; Loibl S; Goldenberg DM; Hong Q; Olivo M; Itri LM; Kalinsky K
NPJ Breast Cancer; 2022 Aug; 8(1):98. PubMed ID: 36038616
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
